Calithera Biosciences stock has undergone multiple analysts rating changes in the recent past. Calithera Biosciences Downgraded by Zacks Investment Research on 10/11/2021. In a note to investors, the firm issued a new rating of Hold. The analysts previously had rating of Buy.
Shares of Calithera Biosciences traded down -$0.01 on Monday, reaching $2.01. 368948 shares of the stock traded hands, compared to its average volume of 535764. Shares of Calithera Biosciences were trading at $2.01 on Monday. The firm’s 50 day moving average is $2.21 and its 200 day moving average is $2.47.Calithera Biosciences has a 12 month low of $1.98 and a 12 month high of $6.19. While on yearly highs and lows, Calithera Biosciences’s today has traded high as $2.03 and has touched $1.98 on the downward trend. See More Analyst Rating at: RATING
Calithera Biosciences Earnings and What to expect:
Calithera Biosciences last issued its earnings data on August 5th, 2021. The biotechnology company reported ($0.19) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.05. The business had revenue of $3 million for the quarter. Calithera Biosciences has generated ($1.31) earnings per share over the last year (($1.11) diluted earnings per share). Earnings for Calithera Biosciences are expected to grow in the coming year, from ($0.83) to ($0.61) per share. Calithera Biosciences has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Thursday, November 4th, 2021 based off prior year’s report dates.
Earnings for Calithera Biosciences are expected to grow in the coming year, from ($0.83) to ($0.61) per share. The P/E ratio of Calithera Biosciences is -1.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Calithera Biosciences is -1.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Calithera Biosciences has a P/B Ratio of 1.39. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.
Calithera Biosciences (CALA) Moving Average Technical Analysis
5 day Moving Average is $2.00 And 5 day price change is $0.03 (1.52%) with average volume for 5 day average is 357,120. While technical analysis for average 20 days shows significant difference, 20 day moving average is $2.14 and 20 day price change is -$0.10 (-4.74%) and average 20 day moving volume is 591,110. 50 day moving average is $2.21 and 50 day price change is $0.06 ( 3.08%) and with average volume for 50 days is : 554,100. 200 day moving average is $2.47 and 200 day price change is -$3.28 (-62.00%) and with average volume for 200 days is : 1,072,394.
Other owners latest trading in Calithera Biosciences :
- On 8/26/2021 shares held by Y Intercept Hong Kong Ltd were 16,387 which equates to market value of $34K and appx 0.00% owners of Calithera Biosciences
- On 8/23/2021 shares held by Morgan Stanley were 985,504 which equates to market value of $2.06M and appx 0.00% owners of Calithera Biosciences
- On 8/17/2021 shares held by Wells Fargo & Company MN were 283,095 which equates to market value of $0.59M and appx 0.00% owners of Calithera Biosciences
- In total Institutional ownership equates to Institutional Ownership Percentage: 63.29% for Calithera Biosciences
See More Analyst Rating at: RATING